

SAVE THE DATE

The Division of Blood Disorders (DBD) is proud to continue its “Webinar Series on Blood Disorders.” This webinar series provides evidence-based information on new research, interventions, emerging issues of interest in blood disorders, as well as innovative approaches in collaborations and partnerships.

Please preregister with Cynthia Sayers at cay1@cdc.gov or 404-498-0020.

TOPIC

Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden

GUEST PRESENTER



Gary E. Raskob, PhD, MSc

Dr. Gary Raskob is Dean of the College of Public Health, and a Professor of Epidemiology and Medicine, at the University of Oklahoma Health Science Center in Oklahoma City, OK. He specializes in research and treatment of blood clotting disorders and the development of antithrombotic drugs (drugs that reduce the formation of blood clots). He also serves as chair of the Medical and Scientific Advisory Board of the National Blood Clot Alliance, an organization dedicated to advancing the prevention, early diagnosis and successful treatment of life-threatening blood clots.

WHEN

THURSDAY, NOVEMBER 6, 2014

2:00–3:00pm EST

WEBINAR

In this webinar, Dr. Raskob will review the disease burden from venous thromboembolism (VTE), and discuss strategies to reduce this burden through prevention of both first time and recurrent clots. He will also describe the clinical features of the two components that together comprise VTE: deep vein thrombosis (DVT), a condition in which a blood clot forms in a deep vein of the body, usually the leg, and pulmonary embolism (PE), the condition that occurs when a blood clot breaks away and travels to the lungs and can be fatal. Dr. Raskob will review what is known about the risk factors for VTE and discuss steps that people can take to reduce their risks.

The overall approach to treatment will be discussed, including the goals of treatment and the roles of anticoagulant therapy (drug therapy to prevent the clotting of blood), thrombolytic therapy (the use of drugs to break up or dissolve blood clots) and vena cava filters (a medical device inserted into a major vein to prevent a blood clot from entering the lungs). The results of recent clinical trials of new oral anticoagulants will be reviewed, with discussion of how these findings may help to reduce the disease burden of VTE. Finally, evidence-based recommendations from practice guidelines as well as strategies for preventing new cases of VTE will be reviewed.

LEARNING OBJECTIVES

After this webinar, the participant will be able to:

- ▶ Describe the US and global disease burden of VTE.
- ▶ Describe the clinical features of VTE and the difference between provoked and unprovoked VTE.
- ▶ Describe the risk factors for VTE.
- ▶ List the steps that people can take to reduce their risk of VTE.
- ▶ Discuss the evidence-based recommendations for the treatment of VTE.
- ▶ Describe how recent advances in oral anticoagulant therapy may help reduce the disease burden from VTE.
- ▶ Describe evidence-based strategies for the prevention of new cases of VTE.

WHO SHOULD ATTEND

This webinar is free and open to public health professionals, clinicians, and researchers who desire more information about venous thromboembolism. Advance preregistration is required and the number of attendees is limited.

National Center on Birth Defects and Developmental Disabilities
Division of Blood Disorders

